Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Jul 31, 2023 7:15am

335 Views

Post# 35564290

7.3B$ takeover

7.3B$ for a biotech that only has 1 FDA approval treatment. That's in the usual range we often see for a takeover. And this is for a rare condition.

https://www.fiercepharma.com/pharma/biogen-ponies-73b-rare-disease-specialist-reata-and-potential-blockbuster-skyclarys

The approval of Skyclarys was the first in the 21-year history of Reata. The company has a few investigational drugs for other neurological conditions in the pipeline, though none are in the late stages of development.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing